comparemela.com

Latest Breaking News On - Astella new drug application - Page 1 : comparemela.com

Astellas VEOZAH™ (fezolinetant) Approved by U S FDA for Treatment of Vasomotor Symptoms Due to Menopause

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA).

United statesAstellas pharmaNaoki okamuraGenevieve neal perryDrug administrationJ public healthAstellas pharma incAstellas incHead of biopharma developmentSchool of medicine department obstetricsPrnewswire astellas pharma incHealth qual life outcomesFull interactive multimediaMedicine departmentMarci englishVice president

Astellas VEOZAH™ (fezolinetant) Approved by U S FDA for Treatment of Vasomotor Symptoms Due to Menopause

VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause TOKYO, May 12, 2023 /PRNewswire/ Astellas Pharma Inc. today. | June 14, 2023

United statesGenevieve neal perryNaoki okamuraAstellas pharmaPrnewswire astellas pharma incHealth qual life outcomesSchool of medicine department obstetricsAstellas pharma incJ public healthDrug administrationAstellas incHead of biopharma developmentFull interactive multimediaMedicine departmentMarci englishVice president

Astellas Provides Update on Fezolinetant New Drug Application in U S

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the U.S. Food and Drug Administration.

Kenji yasukawaAhsan arozullahAstellas pharma incHead of development therapeutic areasDrug administrationPrnewswire astellas pharma incPrescription drug user fee actSenior vice presidentDevelopment therapeutic areasAstella new drug applicationFocus area approachAstellas pharma inc

Fezolinetant NDA Accepted for Vasomotor Symptoms With Menopause

The FDA has accepted the NDA for fezolinetant for the treatment of moderate to severe vasomotor symptoms associated with menopause.

United statesAhsan arozullahAstellas pharma incAmerican college of obstetriciansAmerican menopause societyHead of development therapeutic areasDrug administrationNew drug applicationPrescription drug user fee actSenior vice presidentDevelopment therapeutic areasAstella new drug applicationAccessed augustAmerican collegeGynecologists annualNorth american menopause society

vimarsana © 2020. All Rights Reserved.